Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Molecular Response Patterns in Relapsed/Refractory AML Patients Treated with Selinexor and Chemotherapy

Blood (2021) 138 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2021-151091

Published: 2021

Journal Articles

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Sonja Loges, MD, PhD, Michael Heuser, MD, Joerg Chromik, Carlos E Vigil, MD, Peter Paschka, MD, Isabel Ben-Batalla, PhD, Nuray Akyüz, David Micklem, Robert Holt, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn Gjertsen, MD PhD

Blood (2018) 132 (Supplement 1): 2672.

https://doi.org/10.1182/blood-2018-99-120380

Published: 2018

Journal Articles

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Sonja Loges, MD PhD, Bjørn Tore Gjertsen, Michael Heuser, MD, Joerg Chromik, Isabel Ben-Batalla, Nuray Akyüz, David Micklem, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1375.

https://doi.org/10.1182/blood.V130.Suppl_1.1375.1375

Published: 2017

Journal Articles

Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)

Blood (2016) 128 (22): 4038.

https://doi.org/10.1182/blood.V128.22.4038.4038

Published: 2016

Journal Articles

BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles

Loges Sonja, Bjorn T. Gjertsen, Michael Heuser, Jörg Chromik, Isabel Ben Batalla, Nuray Akyüz, PhD, David Micklem, Anthony Brown, Jim Lorens, Maxim Kebenko, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 592.

https://doi.org/10.1182/blood.V128.22.592.592

Published: 2016

Journal Articles

Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study

Walter Fiedler, MD, Jörg Chromik, Maxim Kebenko, Felicitas Thol, MD, Arne Trummer, MD, Chirstoph Schünemann, Christian H. Brandts, MD, Anne Köhler, Vera Schlipfenbacher, Carsten Bokemeyer, MD, Susann Theile, Anne L. Kranich, Michael Heuser, MD

Blood (2015) 126 (23): 3789.

https://doi.org/10.1182/blood.V126.23.3789.3789

Published: 2015

Journal Articles

Favorable Outcome in a Large Cohort of Prospectively Treated Adult Patients with T-Lymphoblastic Lymphoma (T-LBL) Despite Slowly Evolving Complete Remission Assessed By Conventional Radiography

Nicola Gökbuget, MD, Andrea Wolf, Matthias Stelljes, MD, Andreas Hüttmann, MD, Eike C. Buss, Andreas Viardot, Kalina Brandt, MD, Maike de Wit, MD, Norbert Frickhofen, MD, Maxim Kebenko, MD, Mustafa Kondakci, MD, Doris Kraemer, MD, Stefan Schwartz, MD, Hubert Serve, MD, Karsten Spiekermann, MD, Reingard Stuhlmann, MD, Albrecht Reichle, Dieter Hoelzer, MD

Blood (2014) 124 (21): 370.

https://doi.org/10.1182/blood.V124.21.370.370

Published: 2014

Journal Articles

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Walter Fiedler, MD, Sabine Kayser, Maxim Kebenko, M.D., Jürgen Krauter, MD, PhD, Helmut R. Salih, M.D., Katharina Götze, M.D., Daniela Späth, MSc, Gudrun Göhring, MD, Veronica Teleanu, MD, Konstanze Döhner, MD, Arnold Ganser, Hartmut Döhner, MD, Richard F Schlenk, MD

Blood (2012) 120 (21): 1483.

https://doi.org/10.1182/blood.V120.21.1483.1483

Published: 2012

NARROW

Molecular Response Patterns in Relapsed/Refractory AML Patients Treated with Selinexor and Chemotherapy

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)

BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles

Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study

Favorable Outcome in a Large Cohort of Prospectively Treated Adult Patients with T-Lymphoblastic Lymphoma (T-LBL) Despite Slowly Evolving Complete Remission Assessed By Conventional Radiography

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only